GERMANTOWN, MD and ALTRINCHAM, UK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- GERMANTOWN, MD and ALTRINCHAM, UK — September 30, 2025 — Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio”), an ...
SAN DIEGO, Oct. 24, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and clinical ...
GERMANTOWN, Md./ALTRINCHAM, U.K. - Barinthus Biotherapeutics plc (NASDAQ:BRNS), whose shares have surged over 40% in the past week and currently trade at $1.48, and privately held Clywedog ...
Barinthus Biotherapeutics (BRNS) and Clywedog Therapeutics entered into a definitive merger agreement to combine in an all-stock transaction. The newly combined company will advance a novel portfolio ...
The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being studied for the prevention/reversal of Type 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results